[go: up one dir, main page]

RU2012108110A - Применение меланокортинов для лечения дислипидемии - Google Patents

Применение меланокортинов для лечения дислипидемии Download PDF

Info

Publication number
RU2012108110A
RU2012108110A RU2012108110/15A RU2012108110A RU2012108110A RU 2012108110 A RU2012108110 A RU 2012108110A RU 2012108110/15 A RU2012108110/15 A RU 2012108110/15A RU 2012108110 A RU2012108110 A RU 2012108110A RU 2012108110 A RU2012108110 A RU 2012108110A
Authority
RU
Russia
Prior art keywords
arg
cys
ala
trp
phe
Prior art date
Application number
RU2012108110/15A
Other languages
English (en)
Inventor
Хэзер А. ХЕЙЛЕМ
Майкл Девитт КАЛЛЕР
Original Assignee
Ипсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Фарма С.А.С. filed Critical Ипсен Фарма С.А.С.
Publication of RU2012108110A publication Critical patent/RU2012108110A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1. Способ лечения дислипидемии у субъекта, нуждающегося в этом, включающий периферическое введение эффективного количества агониста рецептора-4 меланокортина для лечения дислипидемии у указанного субъекта, нуждающегося в этом.2. Способ по п.1, где указанное лечение дислипидемии происходит в результате снижения в сыворотке уровней холестерина, триглицеридов, холестеринового липопротеина низкой плотности, свободных жирных кислот или повышения уровней холестеринового липопротеина высокой плотности, или любых сочетаний указанного.3. Способ по п.1, где указанный субъект страдает стеатозом печени.4. Способ по п.3, где указанный стеатоз печени представляет собой неалкогольную жировую болезнь печени или алкогольную жировую болезнь печени.5. Способ по п.4, где указанная неалкогольная жировая болезнь печени или алкогольная жировая болезнь печени сопровождается стеатонефритом, стеатонекрозом, воспалением печеночной доли, баллонирующей дегенерацией, фиброзом, циррозом или раком или их любой комбинацией.6. Способ по п.1, где указанный агонист рецептора-4 меланокортина, используемый для лечения дислипидемии, выбран из группы, состоящей из следующих соединений:Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHAc-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH;Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH;Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH;D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH;D-Phe-c(Cys-His-D-Phe-Arg-Trp--Ala-D-Cys)-Thr-NH;D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH;Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH;Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH;Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys--Ala-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(D

Claims (12)

1. Способ лечения дислипидемии у субъекта, нуждающегося в этом, включающий периферическое введение эффективного количества агониста рецептора-4 меланокортина для лечения дислипидемии у указанного субъекта, нуждающегося в этом.
2. Способ по п.1, где указанное лечение дислипидемии происходит в результате снижения в сыворотке уровней холестерина, триглицеридов, холестеринового липопротеина низкой плотности, свободных жирных кислот или повышения уровней холестеринового липопротеина высокой плотности, или любых сочетаний указанного.
3. Способ по п.1, где указанный субъект страдает стеатозом печени.
4. Способ по п.3, где указанный стеатоз печени представляет собой неалкогольную жировую болезнь печени или алкогольную жировую болезнь печени.
5. Способ по п.4, где указанная неалкогольная жировая болезнь печени или алкогольная жировая болезнь печени сопровождается стеатонефритом, стеатонекрозом, воспалением печеночной доли, баллонирующей дегенерацией, фиброзом, циррозом или раком или их любой комбинацией.
6. Способ по п.1, где указанный агонист рецептора-4 меланокортина, используемый для лечения дислипидемии, выбран из группы, состоящей из следующих соединений:
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trpß-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;
Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-ß-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-ß-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-ß-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-ß-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-ß-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-ß-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;
Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
D-Phe-c(Cys-His-D-Phe-hArg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Bip-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-hArg-Bip-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-ß-Ala-Lys)-NH2;
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-ß-Ala-Lys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-ß-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(ß-Ala)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-Gln-(Arg)5-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-(Arg)5-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)4-Gln-Arg-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Aib-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)3-Gln-(Arg)2-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Gln-(Lys)2-(Arg)5-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)5-Gln-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2; ;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-ß-Ala-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-ß-Ala-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-ß-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro)2-Lys-Asp-NH2;
c[Гидантоин(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;
c[Гидантоин(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин (C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;
c[Гидантоин(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;
c[Гидантоин(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;
c[Гидантоин(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH2;
Гидантоин(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Гидантоин(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
c[Гидантоин(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2,
c[Гидантоин(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2;
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH2;
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; и
Ac-D-Arg-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2
или их фармацевтически приемлемых солей.
7. Способ по п.6, где указанное соединение представляет собой Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 или его фармацевтически приемлемую соль.
8. Способ по п.6, где указанное соединение представляет собой гидантоин(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2 или его фармацевтически приемлемую соль.
9. Способ по любому из пп.1-8, где указанный субъект имеет ожирение, избыточную массу, нормальную массу или является худым.
10. Способ по п.9, где указанный субъект страдает диабетом II типа.
11. Способ по п.1, где указанное периферическое введение является пероральным, подкожным, внутрибрюшинным, внутримышечным, внутривенным, ректальным, трансдермальным или интраназальным.
12. Способ по п.11, где указанное введение осуществляется непрерывно, ежечасно, четыре раза в день, три раза в день, два раза в день, один раз в день, один раз через день, два раза в неделю, один раз в неделю, введением раз в две недели, раз в месяц или раз в два месяца.
RU2012108110/15A 2009-08-05 2010-07-30 Применение меланокортинов для лечения дислипидемии RU2012108110A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
US61/273,488 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
RU2012108110A true RU2012108110A (ru) 2013-09-10

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012108110/15A RU2012108110A (ru) 2009-08-05 2010-07-30 Применение меланокортинов для лечения дислипидемии

Country Status (12)

Country Link
US (2) US20120135923A1 (ru)
EP (1) EP2461681A4 (ru)
JP (1) JP2013501053A (ru)
KR (1) KR20120059520A (ru)
CN (1) CN102548399A (ru)
AU (1) AU2010279719A1 (ru)
BR (1) BR112012002445A2 (ru)
CA (1) CA2769883A1 (ru)
IN (1) IN2012DN01493A (ru)
MX (1) MX2012001513A (ru)
RU (1) RU2012108110A (ru)
WO (1) WO2011017209A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555522T3 (es) 2007-11-05 2016-01-04 Ipsen Pharma S.A.S. Uso de melanocortinas para tratar la sensibilidad a la insulina
CN102686601A (zh) * 2009-11-16 2012-09-19 益普生制药股份有限公司 合成Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2的方法
BR112013027222B1 (pt) * 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
SI3539551T1 (sl) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
EP1809667A1 (en) * 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP3925614A3 (en) * 2005-07-08 2022-03-23 Ipsen Pharma Melanocortin receptor ligands
CA2614678A1 (en) * 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ligands of melanocortin receptors
CA2689016C (en) * 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
ES2555522T3 (es) * 2007-11-05 2016-01-04 Ipsen Pharma S.A.S. Uso de melanocortinas para tratar la sensibilidad a la insulina

Also Published As

Publication number Publication date
AU2010279719A1 (en) 2012-03-01
BR112012002445A2 (pt) 2015-10-13
EP2461681A4 (en) 2013-04-24
MX2012001513A (es) 2012-05-22
EP2461681A1 (en) 2012-06-13
US20120135923A1 (en) 2012-05-31
KR20120059520A (ko) 2012-06-08
US20130331324A1 (en) 2013-12-12
WO2011017209A1 (en) 2011-02-10
JP2013501053A (ja) 2013-01-10
IN2012DN01493A (ru) 2015-06-05
CA2769883A1 (en) 2011-02-10
CN102548399A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
RU2012108110A (ru) Применение меланокортинов для лечения дислипидемии
RU2010122897A (ru) Применение меланокортинов для лечения чувствительности к инсулину
ES2354282T3 (es) Análogos peptídicos inhibidores de la hepatitis c.
RU2014111472A (ru) Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1
AU2014340303B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
FI67539B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptidyl-ng-karboxyl-arginaldehyder
JP4779971B2 (ja) ヒストンデアセチラーゼ阻害剤とトポイソメラーゼｉｉ阻害剤とからなる抗腫瘍剤
EA201792541A2 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
EP2764871A1 (en) Methods for the prevention or treatment of heart failure
RU2011105821A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
MX2009007830A (es) Inhibidor de rechazo cronico.
MX2008015337A (es) Metodo y compuesto para el tratamiento de estenosis valvular.
JP2013503110A5 (ru)
RU2012134974A (ru) Стабилизированное соединение гормона роста
Caron et al. Protein digestion and energy homeostasis: How generated peptides may impact intestinal hormones?
EP2714716A1 (en) Matriptase inhibitors and uses thereof against orthomyxoviridae infections
Schiffrin Endothetin: role in hypertension
WO2019246298A1 (en) Compositions and methods for the reduction or treatment of fibrosis
AU2012286594A1 (en) Modulators of protease activated receptors
AU2016297311B2 (en) Novel peptide and use thereof
FI3749353T3 (fi) Nemolitsumabi keskivaikeita–vaikeita hilseilykohtia aiheuttavan atooppisen ihottuman hoidossa
JP5940542B2 (ja) 細胞導入ペプチドと皮膚導入促進剤とを組み合わせた皮膚導入システムおよび美白剤
US20150238449A1 (en) Benzenetricarboxylic acid and methods of use
WO2022265697A1 (en) Compositions for treating viral infections and methods for same

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20131121